You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR SULFANILAMIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for SULFANILAMIDE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04217967 ↗	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients	Recruiting	Beijing Chao Yang Hospital	Phase 4	2020-01-03	The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
NCT04217967 ↗	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients	Recruiting	Beijing Jishuitan Hospital	Phase 4	2020-01-03	The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
NCT04217967 ↗	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients	Recruiting	Jilin Provincial Tumor Hospital	Phase 4	2020-01-03	The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
NCT04217967 ↗	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients	Recruiting	Peking University First Hospital	Phase 4	2020-01-03	The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
NCT04217967 ↗	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients	Recruiting	Peking University Third Hospital	Phase 4	2020-01-03	The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for SULFANILAMIDE

Condition Name

Chart
Table

Condition Name for SULFANILAMIDE
Intervention	Trials
Multiple Myeloma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for SULFANILAMIDE
Intervention	Trials
Neoplasms, Plasma Cell	1
Multiple Myeloma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SULFANILAMIDE

Trials by Country

Map
Table

Trials by Country for SULFANILAMIDE
Location	Trials
China	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SULFANILAMIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for SULFANILAMIDE
Clinical Trial Phase	Trials
Phase 4	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for SULFANILAMIDE
Clinical Trial Phase	Trials
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SULFANILAMIDE

Sponsor Name

Chart
Table

Sponsor Name for SULFANILAMIDE
Sponsor	Trials
Beijing Chao Yang Hospital	1
Beijing Jishuitan Hospital	1
Jilin Provincial Tumor Hospital	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for SULFANILAMIDE
Sponsor	Trials
Other	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.